| Trial Name: |
LPI 1404 (Suspended)
|
| Intro: |
A Phase II Multicenter Study of ONTAK (Denileukin Diftitoxin) in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma |
| Condition: |
|
| Description: |
This research study is being done to find out if the study drug, ONTAK (denileukin diftitox), can shrink or slow the growth of B-cell non-Hodgkin’s lymphoma (NHL) in patients whose disease has not responded to prior treatments or has relapsed after an initial response to prior treatments. Patients will be treated with ONTAK for 3 days in a row during the first week, then one-time per week for at least 8 weeks, then depending upon the patient’s response, 8 additional times (once per week). After 16 weeks of treatment, additional monthly doses may be given. |
| Criteria: |
- Relapsed/refractory B-cell
- NHL Histological documentation of diffuse large B-cell lymphoma, follicular lymphoma (grade 1, 2 or 3), small lymphocytic lymphoma, or transformed B-cell lymphoma
- Measurable disease, with at least one lymph node or tumor mass measuring 4 cm2
- ECOG performance status 0-2
- Failure to respond or progression of disease after 2 prior treatment regimens
- Adequate bone marrow, liver, and kidney organ function
|
| Contact: |
For Cancer Information, Current Clinical Trials, and Referral to a Physician please call (216) 844-5432 or (800) 641-2422 |
Participant Confidentiality:
All information regarding participation in Clinical Trials is treated with the
utmost confidentiality. University Hospitals Case Medical Center and the
Division of Clinical Research recognize and respect the confidentiality of this
information. Access to information related to clinical trials and their
participants is restricted to authorized clinical trials personnel only.
Back